Abstract:OBJECTIVES:To evaluate the clinical significance of flow cytometry (FCM) to detect the cytomegalovirus (CMV) PP65 antigen in patients with CMV infection. METHODS:Samples from 35 patients without CMV infection were used as negative control. The definite diagnosis of CMV infection was based on the national criteria for CMV infection. All 136 patients with CMV infection were examined with the FCM to detect CMV PP65 antigen, real-time fluorescence quantitative-polymerase chain reaction assay (RFQ-PCR) to detect CMV-DNA and ELISA to measure the serum level of IgM antibody against CMV. The results of these 3 assays in 2 groups (isolated organ involvement and disseminated diseases) were compared and the significance of PP65 antigenemia was evaluated. A short-term follow-up was undertaken in 18 patients. RESULTS:The percentages of PP65 positivity in blood mononuclear cells (MNC) and polymorphic nuclear leukocyte (PMNL) from 35 negative control patients were 0.21% +/- 0.09% with a range of 0 - 0.41% and 0.24% +/- 0.10% with a range of 0.12% - 0.48%, respectively, which were not significantly different (t = 0.425, P > 0.05). The 95(th) percentiles (P(95)) of PP65 in MNC and PMNL were 0.39% and 0.45%, respectively, so a cutoff value of >/= 0.50% was set. Of the 136 patients with CMV infection, 118 samples from 118 patients were positive for PP65 antigenemia with a positive rate of 86.8%, which was not statistically different from that (90.4%, chi(2) = 0.91, P > 0.05) of CMV-DNA detected by RFQ-PCR assay but it was significantly higher than that (45.6%, chi(2) = 51.50, P < 0.005) of the detection by IgM measurement. PP65 detection was correlated with urine CMV DNA amplification (chi(2) = 63.78, P < 0.01) while the different detection rates between the two assays were not statistically significant (chi(m)(2) = 1.78,P > 0.05). PP65 detection was not correlated with serum IgM measurement while the detection rates between the two were significantly different (chi(m)(2) = 52.92,P < 0.01). No significant difference was found between the detection rates of CMV infection in MNC (45/53, 84.9%) and PMNL (43/53, 81.1%) (chi(m)(2) = 0.25, P > 0.05). Higher PP65 antigenemia level was correlated with systemic CMV infection, while lower level of PP65 was either in the patients with isolated organ involvement by CMV (chi(2) = 38.51, P < 0.005) or less severe in patient's situation. PP65 antigenemia of CMV infection returned to lower level or negative in recovery stage and increased when condition of patients deteriorated. CONCLUSIONS:PP65 antigenemia detection by FCM is effective in the diagnosis of the active CMV infection. Quantitative monitoring of PP65 antigenemia is useful in the evaluation of patients with CMV infection.

Human Cytomegalovirus Pp65 Protein Induces Specific Immune Response

Relationship Between T-cell Receptor Beta Chain Sequences and Human Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Anti-HCMV effect of recombinant protein of HCMV pp65 and combination with Jin-Ye-Bai-Du granules

Tlr Agonists Activate Hpv11 E7-Pulsed Dcs to Promote A Specific T Cell Response in A Murine Model

The clinical significance of CMV - pp65 antigen detcetion in hepatitis B virus (HBV) related hepatocellular carcinoma patients

[Application of Flow Cytometry to Detect PP65 Antigenemia for Diagnosis and Monitoring of Human Cytomegalovirus Infection].

Production of Monoclonal Antibodies Against Phosphoprotein 65 from Human Cytomegalovirus.

Recombinant HCMV UL128 Expression and Functional Identification of PBMC-attracting Activity in Vitro

Specific T-cell Receptor Gene Transfer Enhances Immune Response: A Potential Therapeutic Strategy for the Control of Human Cytomegalovirus Infection in Immunocompromised Patients

Receptor Expression and Responsiveness of Human Peripheral Blood Mononuclear Cells to a Human Cytomegalovirus Encoded CC Chemokine

Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation

Preliminary Exploration of Hla-A*1101-Restricted Human Cytomegalovirus Glycoprotein B-Specific Cd8(+) T Cells in Allogeneic Stem-Cell Transplant Recipients

Expression and Purification of Human Cytomegalovirus Tegument Protein Pp65 and Analysis of Its Immunologic Characteristics

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice

Cytokine responses to major human Cytomegalovirus antigens in mouse model

The Induction of Systemic Lupus Erythematosus by Human Cytomegalovirus Pp65

Evaluation of human cytomegalovirus-specific CD8+ T-cells in allogeneic haematopoietic stem cell transplant recipients using pentamer and interferon-γ-enzyme-linked immunospot assays.

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Immunostimulation by cytomegalovirus (CMV): helper T cell-dependent activation of immunoglobulin production in vitro by lymphocytes from CMV-immune donors